News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and V

Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’.11/05/2017Biotherapeutics News & Views FEATURE Fully human antibodies for therapeutic application – a promise fulfilled from great expectations? It is now 15 years since the FDA approved the first fully human monoclonal antibody (adalimumab, Humira®), heralding a new era in biotherapeutics. Fast forward to 2017, has their promise been realised? In this first issue of Biother


2. Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option A

Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics03/05/2017Potential acquisition tied to clinical milestones of lead candidate MTL-CEBPA, a novel small activating RNA therapeutic in Phase 1/2a development in advanced liver cancerSosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) and MiNA Therapeutics Limited (“MiNA”) announced today that the companies have entered into a definitive agreement under which Sosei will


3. Press Release: Consilium Strategic Communications Strengthens Senior I

Press Release: Consilium Strategic Communications Strengthens Senior International Healthcare Team with the Appointment of Philippa Gardner and Suki Virji 08/05/2017Consilium Strategic Communications, a global leader in strategic healthcare communications, today announces the appointment of Philippa Gardner and Suki Virji to the London office.Philippa has more than 13 years’ experience as a healthcare sell-side analyst covering European biotechnology, life sciences and mid-cap pharma


4.  Adaptimmune Reports First Quarter 2017 Financial Results

 Adaptimmune Reports First Quarter 2017 Financial Results 10/05/2017– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019 –– Initiated study with wholly-owned AFP SPEAR T-cells –– Initial data from three wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) in up to eight tumor indications anticipated in 2017 and 2018 –– Updated NY-ESO data to be presented in an oral pre


5. Interim Results for the Six Months Ended 31 March 2017

Interim Results for the Six Months Ended 31 March 2017 17/05/2017Redx (AIM: REDX) announces its interim results for the six months ended 31 March 2017:> Clinical trial application filed for Porcupine inhibitor RXC004> Development candidate chosen for reversible BTK inhibitor RXC005 for drug resistant chronic lymphocytic leukaemia> Strategic restructuring completed post period; estimated £4.2 million annual cost saving> Iain Ross appointed as Non-Executive Chairman of the Bo



Page 25 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019